Clinicopathologic Features of Patients with Serum Prostate-Specific Antigen Levels > 1000 ng/mL

被引：0
|
作者：
Horwath, Michael [1 ]
Oprea-Ilies, Gabriela [2 ]
Osunkoya, Adeboye [1 ]
机构：
[1] Emory Univ, Sch Med, Atlanta, GA USA
[2] Emory Univ, Sch Med, Grady Mem Hosp, Atlanta, GA USA
来源：
LABORATORY INVESTIGATION | 2024年 / 104卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
767
引用
收藏
页码：S962 / S963
页数：2
相关论文
共 50 条
  • [21] Complexed prostate-specific antigen, and complext prostate-specific antigen indices for early detection of prostate cancer in men with total prostate-specific antigen between 2.0 and 4.0 ng/ml
    Reissigl, A
    Remzi, M
    Wiunig, C
    Zlotta, A
    Ravery, V
    Hammerer, P
    Dobronski, P
    Kaisary, A
    Marberger, M
    Djavan, B
    [J]. JOURNAL OF UROLOGY, 2003, 169 (04): : 426 - 427
  • [22] Significance of Serum Testosterone for Prostate-Specific Antigen (PSA) Elevation and Prediction of Prostate Cancer in Patients with PSA Above 10 ng/ml
    Koo, Jin Mo
    Shim, Bong Suk
    [J]. KOREAN JOURNAL OF UROLOGY, 2010, 51 (12) : 831 - 835
  • [23] Prostate-Specific Antigen Density as a Powerful Predictor of Extracapsular Extension and Positive Surgical Margin in Radical Prostatectomy Patients with Prostate-Specific Antigen Levels of Less than 10 ng/ml
    Chang, Jin-Seok
    Choi, Hoon
    Chang, Young-Seop
    Kim, Jin-Bum
    Oh, Mi Mi
    Moon, Du Geon
    Bae, Jae Hyun
    Cheon, Jun
    [J]. KOREAN JOURNAL OF UROLOGY, 2011, 52 (12) : 809 - 814
  • [24] Percent decrease of serum prostate-specific antigen after dutasteride administration is equivalent in men with clinical benign prostatic hyperplasia having baseline prostate-specific antigen >10 ng/mL and those having baseline prostate-specific antigen 2.5-10 ng/mL
    Takeshita, Hideki
    Kawakami, Satoru
    Yano, Akihiro
    Okada, Yohei
    Morozumi, Makoto
    Yamada, Takumi
    [J]. INTERNATIONAL JOURNAL OF UROLOGY, 2017, 24 (03) : 238 - 239
  • [25] Effect of prostate manipulation on the serum levels of complexed prostate-specific antigen and total prostate-specific antigen
    Long, Ronan
    Giri, Subhasis
    Diver, Sean
    Duddy, Lorna
    McKeown, Declan
    Moran, Kevin
    [J]. INTERNATIONAL JOURNAL OF UROLOGY, 2006, 13 (07) : 947 - 950
  • [26] M1 prostate cancer with a serum level of prostate-specific antigen less than 10 ng/mL
    Yamamoto, S
    Ito, T
    Akiyama, A
    Aizawa, T
    Miki, M
    Tachibana, M
    [J]. INTERNATIONAL JOURNAL OF UROLOGY, 2001, 8 (07) : 374 - 379
  • [27] Comparison of two investigative assays for the complexed prostate-specific antigen in total prostate-specific antigen between 4.1 and 10.0 ng/mL
    Okegawa, T
    Noda, H
    Nutahara, K
    Higashihara, E
    [J]. UROLOGY, 2000, 55 (05) : 700 - 704
  • [28] Our Prostate Biopsy Results in The Patients with Prostate Specific Antigen Levels Below 4 ng/ml
    Aydemir, Huseyin
    Budak, Salih
    Kumsar, Sukru
    Kose, Osman
    Saglam, Hasan Salih
    Adsan, Oztug
    [J]. JOURNAL OF CLINICAL AND ANALYTICAL MEDICINE, 2015, 6 (03) : 320 - 323
  • [29] Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate-specific antigen levels ≤ 10 ng/mL
    Stephan, C
    Jung, K
    [J]. CANCER, 2004, 100 (09) : 1988 - 1989
  • [30] Prostate-specific antigen cutoff of 2.6 ng/ml for prostate cancer screening is associated with favorable pathologic tumor features - Reply
    Krumholtz, JS
    Carvalhal, GF
    Ramos, CG
    Smith, DS
    Thorson, P
    Yan, Y
    Humphrey, PA
    Roehl, KA
    Catalona, WJ
    [J]. UROLOGY, 2002, 60 (03) : 474 - 474
12345